image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k |
|---|---|---|
f15d7bdbfa3ca446a0fa6cfc6699259fd4d097502d0fee2780769dd1aa2789d2.png | simple | <table><tr><td></td><td></td><td>B2</td><td>HTK</td><td>Euro Collins </td></tr><tr><td>Osmolality (mosm/kg)</td><td></td><td>323</td><td>310</td><td>406</td></tr><tr><td>Ions (mmol/l)</td><td>Na<sup>+</sup></td><td>22</td><td>15</td><td>10</td></tr><tr><td></td><td>K<sup>+</sup></td><td>150</td><td>9</td><td>115</td></... |
71d91f59326e819e716b4352ecd8e0ea544d58dda15907399fab350f9f90132e.png | simple | <table><tr><td>Primer name</td><td>Oligonucleotide</td><td>Product length</td><td>Product name</td></tr><tr><td><i>crdPG-1</i></td><td>GTACTCGAGATTGTCGGCAGTCCAG</td><td>607</td><td><i>crdP</i></td></tr><tr><td><i>crdPG-2</i></td><td>AGCTCCTCGCCCTTGCTCACCATGAAATCAACTCCTCTGT</td><td></td><td></td></tr><tr><td>GFP-1</td><... |
02fa9e3b3695bb07995a91c076ffd9114130a8bef740627554a03214d9a49819.png | simple | <table><tr><td>lectin</td><td>time (dpi/dpe)<sup>a</sup></td><td>mucus<sup>b</sup></td><td>SMC<sup>c</sup></td><td>MNC<sup>d</sup></td></tr><tr><td>UEAI</td><td>0</td><td>+/-</td><td>-</td><td>++</td></tr><tr><td></td><td>14</td><td>+/-</td><td>+/-</td><td>++</td></tr><tr><td></td><td>21</td><td>+</td><td>+</td><td>++<... |
405ee029d57ac9a6a14682fb572ab9fbf106ca3f216a07d6bd2bb2349c5c39f1.png | complex | <table><tr><td rowspan="2">HRV Index</td><td rowspan="2">Sitting Variable</td><td colspan="4">Crude Model (<i>N</i> = 126)</td><td colspan="4">Primary Adjusted Model (<i>N</i> = 126)</td></tr><tr><td>B</td><td>95%CI Low</td><td>High</td><td><i>p</i></td><td>B</td><td>95%CI Low</td><td>High</td><td><i>p</i></td></tr><tr... |
f631aa3f4a2f8daf322cde303f21a16276a8cd29ecd8e1517ca0b835913511a4.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">24‐hr mean <i>T</i><sub>b</sub> (°C)</td><td colspan="2">24‐hr maximum <i>T</i><sub>b</sub> (°C)</td></tr><tr><td>No feed</td><td>Feed</td><td>No feed</td><td>Feed</td></tr><tr><td colspan="5"><i>Sex</i></td></tr><tr><td>Male (<i>n</i> = 10)</td><td>... |
50a94dab4a1ce3e9c4e4b57a2e32f154c819b6005ae34e90eab5c91d6211678d.png | complex | <table><tr><td></td><td></td><td colspan="2">Intervention (home visit)</td><td></td></tr><tr><td>Variable</td><td></td><td>No (<i>N</i> = 221)</td><td>Yes (<i>N</i> = 262)</td><td><i>P</i>-value</td></tr><tr><td colspan="5">Age (years)</td></tr><tr><td></td><td>Age (±SD)</td><td>30.40 ± 8.57</td><td>30.49 ... |
0c83a1147e3740adb25b22a353b46b90d5501549ebe45119e05a4d5f5eeb6940.png | simple | <table><tr><td>Preparation</td><td>Average finish line width (mm)</td></tr><tr><td>CCC 46</td><td>0.5</td></tr><tr><td>MCC 24</td><td>(0.5 + 1.2)/2 = 0.85</td></tr><tr><td>MCC 46</td><td>(0.5 + 0.8)/2 = 0.65</td></tr><tr><td>ACC 21</td><td>1</td></tr></table> |
685a7b6d4c8cab5d594648324ae46b7d3c3a714af7c620f7010a241bceb3ce16.png | complex | <table><tr><td rowspan="2">Peptide</td><td colspan="3">COX-1</td><td colspan="3">COX-2</td></tr><tr><td>be</td><td>ir</td><td>hb</td><td>be</td><td>ir</td><td>hb</td></tr><tr><td>GMD</td><td>−1.20</td><td>23</td><td>1</td><td>−39.87</td><td>21</td><td>3</td></tr><tr><td>GHE</td><td>−0.56</td><td>25</t... |
e2397db4488c776e18dd9b47f396e2202806fccd8849626da8a98eb717712f27.png | complex | <table><tr><td>Antibody</td><td colspan="4">Growth inhibition (%) over the period of cultivation</td></tr><tr><td>1 mg/ml IgG</td><td colspan="4"></td></tr><tr><td></td><td>Day 1</td><td>Day 2</td><td>Day 3</td><td>Day 4</td></tr><tr><td>GST</td><td>9.5±9.9</td><td>5.3±5.5</td><td>10.7±7.4</td><td>10.5&#... |
7a0b5fc576fcc9ae4b83f9df105978c8d3efdc33dede17bd460f67298966d80d.png | simple | <table><tr><td>TB CX-test</td><td>AFB staining (+)</td><td>AFB staining (−)</td><td>Totals</td></tr><tr><td>TB CX-test(+)</td><td>12</td><td>1*</td><td>13</td></tr><tr><td>TB CX-test(−)</td><td>0</td><td>83</td><td>83</td></tr><tr><td>Totals</td><td>12</td><td>84</td><td>96</td></tr></table> |
e370057b32d6f60868bff32a5daec331bcc6d4c058c4d953f70287c461f096d1.png | simple | <table><tr><td><i>Variable</i></td><td><i>Max</i></td><td><i>Min</i></td><td><i>Mean</i></td><td><i>SD</i></td></tr><tr><td>“Income”</td><td>550.00</td><td>0.00</td><td>42.33</td><td>42.65</td></tr><tr><td>“Spent”</td><td>425.00</td><td>1.97</td><td>25.42</td><td>36.86</td></tr><tr><td>“Pi... |
650ddc8f908c2530ed6ffa1d7f2d5e9905654600a7f16d9ef827c1e527bc1bb3.png | simple | <table><tr><td>Variables</td><td>Mean</td><td>95% CI of the mean</td><td>Statistics (<i>P</i> values)</td></tr><tr><td>IBS symptom score</td><td>1.57</td><td>0.10; 3.05</td><td><i>P</i> = 0.04</td></tr><tr><td>Bacteroides</td><td>−0.01</td><td>−0.11; 0.08</td><td>ns (<i>P</i> = 0.77)</td></tr><tr><td>Faecal... |
9744cc1ccdf3131f2a22be41f3eb022036e9ee8e4459906d8fa10ccf0fdb7b50.png | complex | <table><tr><td rowspan="2"> </td><td rowspan="2">I</td><td colspan="4"><i>T</i><sub>a </sub>(°C)</td></tr><tr><td>400</td><td>450</td><td>500</td><td>550</td></tr><tr><td rowspan="4">Average height (AH) [nm]</td><td>(111)A</td><td>23.4</td><td>25.4</td><td>28.9</td><td>32.2</td></tr><tr><td>(110)</td><td>22.6</td>... |
0b4dd4d3b07343a19c30729e888aaf106bfe31b96a570c698e8f8a66fb30f033.png | complex | <table><tr><td>Reason</td><td>No. of patients</td><td>% patients</td></tr><tr><td colspan="3">Presence of any types of primary disease progression (n = 26)</td></tr><tr><td>Enlargement of tumor</td><td>14</td><td>47</td></tr><tr><td>Elevation of tumor marker</td><td>7</td><td>23</td></tr><tr><td>Carcinomatous pain</td>... |
ec07a5032d8702ce95565fabfba065ee781e5613a275cc64c5ecd2c02e310db6.png | simple | <table><tr><td>Antibodies</td><td>Manufacturer</td><td>Source</td><td>Reactivity</td><td>Dilution</td></tr><tr><td>CD34</td><td>Sigma</td><td>Mouse</td><td>Rat</td><td>1:100</td></tr><tr><td>5-HT</td><td>Immunostar</td><td>Rabbit</td><td>Rat</td><td>1:20,000</td></tr><tr><td>GFAP</td><td>Millipore</td><td>Rabbit</td><t... |
1771cf213ddf45a3c88966e68cfb19ccd1efde7f0e2dc4c99e2281ac158e2994.png | simple | <table><tr><td>sTNF/TNFR1 signaling</td><td> </td></tr><tr><td>sTNF is necessary for the induction of autoimmune diseases [160]</td><td> </td></tr><tr><td>Association of TNF and TNFR1 polymorphisms with PD risk [14, 163]</td><td> </td></tr><tr><td>Association of TNFR1 polymorphism with MS risk [164]</td><td> </td></tr>... |
e70b22037fc754144623387958601c26a41bb363bc4a81d7ab7d6bce02ab03a0.png | simple | <table><tr><td>Structure</td><td>Damage Scale</td><td>Stiffness Adjustment</td><td>Flatfoot Stiffness (N/mm)</td></tr><tr><td>Superomedial spring</td><td>Stage IV</td><td>−7/8th</td><td>39</td></tr><tr><td>Inferomedial spring</td><td>Stage II</td><td>−3/8th</td><td>94</td></tr><tr><td>Talocalcaneal inteross... |
351638ac85eb5236645cefab448cc52cca40e9cd703b5a968b1ea42396b21cfe.png | simple | <table><tr><td>Usage</td><td>AAindex ID</td><td>Physicochemical properties</td></tr><tr><td>100%</td><td>MEEJ800102</td><td>Retention coefficient in HPLC, pH2.1</td></tr><tr><td>91%</td><td>WOLS870102</td><td>Principal property value z2</td></tr><tr><td>87%</td><td>CASG920101</td><td>Hydrophobicity scale from native pr... |
330c5c8fbd6d56041b50591f075f53162948f87c5711fcbd8a80c06d3a490945.png | complex | <table><tr><td></td><td>All patients (<i>n</i> = 1119)</td><td>LBBB (<i>n</i> = 221)</td><td>RBBB (<i>n</i> = 82)</td><td>IVCD (<i>n</i> = 67)</td><td>Narrow QRS (<i>n</i> = 749)</td><td><i>P</i> value</td></tr><tr><td>Age (years)</td><td>51.1 ± 14.7</td><td>57.2 ± 12.0</td><td>53.1 ± 14.7</td><td>52.3 &... |
8e413acbb521002dcc117eb0865f50563dccd173d9d111af80b6e2563c89a230.png | complex | <table><tr><td rowspan="2">Treatment groups</td><td colspan="2">Continuous exposure profile</td><td colspan="2">Cross-over exposure profile</td></tr><tr><td>CC</td><td>TT</td><td>CT</td><td>TC</td></tr><tr><td>CC</td><td></td><td>42</td><td>53</td><td>42</td></tr><tr><td>TT</td><td>42</td><td></td><td>36</td><td>31</td... |
477427e14544cf8b4d86bcb90d99578468231858031f13e6dec36f9f5185b5a9.png | simple | <table><tr><td><i>XXY ID</i></td><td><i>Sequence (XX_Y)</i></td><td><i>N Species</i></td><td><i>freq (%)</i></td><td><i>N changes*</i></td></tr><tr><td>1</td><td>AAaTGAAGAAAAcGAAGA_ATGAAGA</td><td>2</td><td>2.11</td><td>2</td></tr><tr><td>2</td><td>AAaTGAAGAAAATGAAGA_ATGAAGA</td><td>27</td><td>28.42</td><td>1</td></tr>... |
3a1a9be4682b1b0020d79ee4438a467ef50ca77cc37d619a3970c6b1036186a5.png | simple | <table><tr><td>Participants</td><td>Nationality</td><td>Sex</td><td>Age category</td><td>Migratory status</td><td>Health complaints</td><td>Received treatments while undocumented migrant in Denmark</td></tr><tr><td>P01</td><td>Bangladeshi</td><td>Male</td><td>31-40</td><td>Failed asylum seeker</td><td>Dental problems, ... |
587806a7e81461905248c0ba60223492a95de4058bf68fd9ed3ca2d21c6cd781.png | simple | <table><tr><td></td><td>Linear model</td><td>Ordered probit model</td></tr><tr><td>Men 15-44</td><td></td><td></td></tr><tr><td>Gap in VAS</td><td>0.196</td><td>0.186</td></tr><tr><td>Prevalence effect</td><td>-0.082</td><td>-0.102</td></tr><tr><td>Severity effect</td><td>0.239</td><td>0.030</td></tr><tr><td>Interactio... |
0d4bb2438e392ba0f24139e02426d9aae73137f00248a4389b944f1f4eea919b.png | complex | <table><tr><td>Study</td><td>Criteria used for prophylaxis</td><td>Antifungal used for prophylaxis</td><td>Invasive candidiasis</td><td>Commentary</td></tr><tr><td colspan="5">Positive prophylactic studies</td></tr><tr><td>*Slotman et al.1987 [77]</td><td>Abdominal surgery+ ≥ 3 risk factors</td><td>Ketoconazole 2... |
28e2083b97471052974b613071ac37e9d745a7cdc5c6ad86f1e30c4fb4c8382b.png | simple | <table><tr><td>Ptosis</td><td>Group A</td><td>Group B</td></tr><tr><td>Excellent</td><td>89% (57)</td><td>83.9% (52)</td></tr><tr><td>Good</td><td>9.4% (6)</td><td>9.7% (6)</td></tr><tr><td>Fair</td><td>1.6% (1)</td><td>6.4% (4)</td></tr><tr><td>Poor</td><td></td><td></td></tr><tr><td>Very poor</td><td></td><td></td></... |
e2612df633e02c397767c390e5611497d0ad65bc717ec873cfda0df22a949ffd.png | complex | <table><tr><td>NHANES 2001–2010<sup><i>a</i></sup></td><td>Sample size</td><td>Unweighted percent, %</td></tr><tr><td>All</td><td>9,568</td><td>100.0</td></tr><tr><td>Sex</td></tr><tr><td>Male</td><td>4,690</td><td>49.0</td></tr><tr><td>Female</td><td>4,878</td><td>51.0</td></tr><tr><td>Age (years)</td></tr><tr><... |
eaccd4fc0288068d0343323d33e1bcb631f923b1bd70c2ed401ef77da7d90e32.png | simple | <table><tr><td>Gene</td><td>Forward (5′-3′)</td><td>Reverse (5′-3′)</td></tr><tr><td>Egr1</td><td>AACAACCCTACGAGCACCTG</td><td>AAAGGGGTTCAGGCCACAAA</td></tr><tr><td>Fgf2</td><td>GCGACCCACACGTCAAACTA</td><td>CCGTGACCGGTAAGTGTTGTA</td></tr><tr><td>Fgf7</td><td>TGTGGCAATCAAAGGGGTGG</td><td>AAGGCCAC... |
352c4bce167263351912432fa7c3e737097a94db30cf2769098f67891b53e10d.png | complex | <table><tr><td>Category</td><td>Data Elements</td></tr><tr><td rowspan="5">Vascular Access</td><td>Dialysis catheter position</td></tr><tr><td>Dialysis catheter type (acute or tunneled)</td></tr><tr><td>Dialysis catheter manufacturer</td></tr><tr><td>Dialysis catheter size</td></tr><tr><td>Any need for catheter manipul... |
fabf18c090f7d349bebed00f083ee4644892745624b2651ae2edabd0415708bd.png | complex | <table><tr><td>Name</td><td>Description</td><td>Reference</td></tr><tr><td colspan="3">Integrative plasmid set with <i>URA3</i> selection marker flanked with direct repeats</td></tr><tr><td> pCfB126</td><td>pX-2-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB127</td><td>pX-3-USER-URA3-DR</td>... |
ff69e56110217af774f0516f687031ad5779c017a0c16065aeef5575dff1a650.png | simple | <table><tr><td></td><td>Specificity (%)</td><td>Sensitivity (%)</td><td>AUC</td><td>Confidence interval</td></tr><tr><td>Roc 1 (Both H&R scores >0)</td><td>83.3</td><td>61.1</td><td>72.3</td><td>63.61–82.22 %</td></tr><tr><td>Roc 2 (Both H&R scores >1)</td><td>81.4</td><td>67.8</td><td>75.3</td><td>... |
5d9d0331778fe8389db8f27df0967019ccdda0ac8ccbb0dd43994a69f73d7e47.png | simple | <table><tr><td></td><td>PA-PRP (<i>n</i> = 11)</td><td>HA (<i>n</i> = 10)</td></tr><tr><td>Age, mean (SD) years</td><td>49.91 (13.72)</td><td>52.70 (10.30)</td></tr><tr><td>BMI, mean (SD) kg/m<sup>2</sup></td><td>27.92 (11.94)</td><td>30.87 (5.64)</td></tr><tr><td>Previous surgery, no. (%)</td><td>5 (45 %)</td><td>8 (8... |
59e466818280b4311fdf06afb0e03baddd579f9b12960abd754533c280aec613.png | complex | <table><tr><td colspan="2"></td><td>AML(n=11)</td><td>ALL(n=9)</td><td>MM(n=26)</td><td>NHL(n=6)</td><td>HL(n=12)</td><td>P value</td></tr><tr><td colspan="2">IL-6 (pg/mL)</td><td>95.10(55.10-140.90)</td><td>89.90 (61.90-690)</td><td>91.25(4.5-640)</td><td>68.10(33-152.9)</td><td>72.70(32-530)</td><td>0.25</td></tr><tr... |
225a8efed3cedc97320fc1821a74af5639218c81ff4d316cc189ca6502a6658d.png | complex | <table><tr><td colspan="4">Holistic wellness/well-being (encompassing each of physical, psychological, social, spiritual)</td></tr><tr><td>Physical</td><td>Psychological</td><td>Social</td><td>Spiritual</td></tr><tr><td>Biological markers</td><td>Absorption</td><td>Adjustment</td><td>Awareness</td></tr><tr><td>Disabili... |
72b5eba9cf53dcaab08a1d0a4b1f14806eadd15ee88613515fa36c2d563240ae.png | simple | <table><tr><td>Rotarix<sup>® </sup>label</td><td>"In the manufacturing process, porcine-derived materials are used.Porcine circovirus type 1 (PCV-1) is present in Rotarix. PCV-1 is not known to cause disease in humans."</td></tr><tr><td>RotaTeqTM label</td><td>"In the manufacturing process for RotaTeq, a porcine-d... |
289212ed4ab09b7fceea8003c095be736131097335e13f93fed46bc78fbdea1b.png | simple | <table><tr><td>Probe set ID</td><td>Gene Symbol</td><td>Gene Title</td><td>Fold Change in Apc<sup><i>fl</i>/<i>fl </i></sup>p53<sup>-/- </sup>v WT</td></tr><tr><td>1418368_at</td><td>Retnlb</td><td>resistin like beta</td><td>0.002</td></tr><tr><td>1422422_at</td><td>Defcr4</td><td>defensin related cryptdin 4</td><td>27... |
e952de5166425ac9f132bbdcf30b8ae41e4dd18868ab12534f330e3e2c2e49ef.png | simple | <table><tr><td>Acridine orange</td><td>A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.</td></tr><tr><td>Acriflavine</td><td>3,6-Diamino-10-methylacridinium chloride mixture. with 3,6-acr... |
5f1044d6b74f43c39b13e351f5842198f3e5c14ad8b979ee29a55d2298c59cd0.png | simple | <table><tr><td>Loading of MWCNT (wt%)</td><td>Tg by DMA (°C)</td><td>CTE by TMA (×10<sup>−6</sup> K<sup>−1</sup>)</td></tr><tr><td>Control</td><td>161 ± 0.3</td><td>85 ± 0.3</td></tr><tr><td>0.1 </td><td>160 ± 0.1</td><td>89 ± 0.9</td></tr><tr><td>0.25 </td><td>162 ± 0.3</... |
d14421206be65684df13611af7db92daa89f4d7c2a825e03031da99a0c2beb07.png | simple | <table><tr><td> </td><td>Drug(s) resistant to</td><td>Typical diseases</td></tr><tr><td>Name of Bacterium</td><td> </td><td> </td></tr><tr><td> <i>Escherichia coli </i> </td><td>Cephalosporins and fluoroquinolones</td><td>Urinary tract infections and blood stream infections </td></tr><tr><td> <i>Klebsiella pneumoniae <... |
813222bf4a6f7c538aca063fc60e7114a47efa100e479358e333891134f8a78c.png | simple | <table><tr><td> </td><td>Frequency</td><td>Percentage</td></tr><tr><td>Aetiology</td><td> </td><td> </td></tr><tr><td> Unknown</td><td>294</td><td>66.2%</td></tr><tr><td> Stone</td><td>44</td><td>9.9%</td></tr><tr><td> Nephrotic</td><td>22</td><td>5.0%</td></tr><tr><td> Glomerulonephritis (nephritic)</td><td>22</td><td... |
7bf5251b2c367da77d50e300d499b56ce2f8aa8bed7762c2e850e1ded17c4998.png | complex | <table><tr><td>Characteristic</td><td>LN group (n = 14)</td><td><i>P-value</i></td></tr><tr><td>Time since birth of first male child (yr)</td><td></td><td></td></tr><tr><td> 1 to 15 (n = 5)</td><td>9.25 ± 12.37</td><td>NS</td></tr><tr><td> >15 (n = 9)</td><td>5.5 ± 9.6</td><td></td></tr><tr><td>Time since ... |
9baed7b578a3b099560318d20a979cd3ad4e327ecd867b02b67900f64b8b9397.png | simple | <table><tr><td>Methodology Followed</td><td>Start/End Point Needed</td><td>Tube Specific</td><td>No Automation</td><td>Seed Point Needed</td><td>time to detection</td><td>Surgical planning</td><td>Neuro-surgical planning</td><td>Arbitrary objects detection</td><td>Arbitrary image modality</td><td>Fine Vessel Accuracy</... |
127a6dbccac969ba74fb39a9375517577cc1d9f3415611ddd276ee25a2eda951.png | simple | <table><tr><td>No.</td><td>Activity reviewed</td><td>Activities confirmed (Pa)</td><td>Additional predicted activities (Pa<sup>a</sup>)</td></tr><tr><td>78</td><td>Antimicrobial antiviral antineoplastic</td><td>Antineoplastic (sarcoma) (0.413)</td><td>Atherosclerosis treatment (0.924)Genital warts treatment (0.600)</td... |
5b2253cea59e0eac5ee35f21cacc39a2b3a6bc53194e299103045b5a572f69b7.png | complex | <table><tr><td>Mobile phase</td><td>Relation</td><td>Volume (mL)</td><td>Fractions</td><td>Residue (mg)</td></tr><tr><td>Dichloromethane</td><td>100%</td><td>500</td><td>F4.3.1</td><td>0.4</td></tr><tr><td rowspan="3">Dichloromethane : ethyl acetate</td><td rowspan="3">90 : 10</td><td rowspan="3">500</td><td>F4.3.2</td... |
6d7fc47657d18d6bef2e443081c9f96a97a49071789360de652b4e2b97441bac.png | complex | <table><tr><td rowspan="3">Patient</td><td>F<sub>p</sub></td><td>v<sub>e</sub>*</td><td>v<sub>p</sub></td><td>PS</td><td>SUV*</td><td>Cellularity</td><td>Tumor</td></tr><tr><td>(mL.min<sup>−1</sup>.100g<sup>−1</sup>)</td><td>(%)</td><td>(%)</td><td>(mL.min<sup>−1</sup>.100g<sup>−1</sup>)</td><td... |
c3eb3f42444e4a5d5f647e5e83cef3d04eca96bc2ca19027cdf607282dc9ffec.png | simple | <table><tr><td></td><td>B</td><td>S.E.</td><td>Wald</td><td>df</td><td>Sig.</td><td>Exp(B)</td></tr><tr><td>TG</td><td>−0.634</td><td>0.402</td><td>2.489</td><td>1</td><td>0.115</td><td>0.530</td></tr><tr><td>Chol</td><td>0.511</td><td>0.825</td><td>0.384</td><td>1</td><td>0.536</td><td>1.667</td></tr><tr><td>LDL... |
06a8b9f21b315d93b99c4c8cc85784335e0c9e796fd7e361acc34557cfbfb23b.png | complex | <table><tr><td></td><td>Total (N)</td><td>N of Death</td><td>Median survival (months)*</td><td>Mean survival (months)</td><td><i>P</i> value</td></tr><tr><td colspan="6">Oct-4</td></tr><tr><td>Positive</td><td>58</td><td>26</td><td>43</td><td>45.1</td><td>0.022</td></tr><tr><td>Negative</td><td>36</td><td>8</td><td>*</... |
b2b2286ded5c376afb53197285e1cd028f5b30c1645eab01edcf80e9fa378f83.png | simple | <table><tr><td>Ref.</td><td>Textural features</td><td>Classifier</td><td>Accuracy</td></tr><tr><td>Mannivannan [23]</td><td>Four types of local features with CPM-BoW encoding</td><td>Ensemble SVMs</td><td>87.09%</td></tr><tr><td>Sansone [87]</td><td>Dense local descriptors with BoW encoding</td><td>SVM</td><td>83.64%</... |
08b2bbc68a9f49274003cad83b71203812102812744b6c5113f1f89f267565db.png | complex | <table><tr><td>Compounds</td><td>Signals</td><td>Assign of Signals</td><td>S/N</td><td>Signal Intensity</td><td>Quantitative Value (mg)</td></tr><tr><td rowspan="3">CTX3C</td><td>H</td><td>Hydroxyl group 44</td><td>81</td><td>0.40</td><td>0.4060 ± 0.0038</td></tr><tr><td>I</td><td>Olefin 2, 3, 13, 14, 18, 19, 23, ... |
d506ebb93445d098d14658c8ddd82b94868305765ca7d60a1fb2b653ecb13806.png | complex | <table><tr><td rowspan="2">Termb</td><td rowspan="2">KEGG pathway</td><td rowspan="2">Countc</td><td rowspan="2">%d</td><td colspan="2">Detected proteome backgrounde</td><td colspan="3">Entire proteome backgroundf</td></tr><tr><td><i>P</i>‐value</td><td>Fold enrichment</td><td><i>P</i>‐value</td><td>Fold en... |
55a841e20984576146e5de59e6eced46d8461f998c1e4edf1014b369fc2a55f4.png | simple | <table><tr><td></td><td>CSX (−)MetX (−)(N = 39)</td><td>CSX (+)MetX (−)(N = 35)</td><td>CSX (−)MetX (+)(N = 15)</td><td>CSX (+)MetX (+)(N = 24)</td><td><i>p</i><sup>a</sup></td><td><i>p</i><sup>b</sup></td></tr><tr><td>Adiponectin (μg/mL)</td><td>12.3 (7.0, 18.9)</td><td>3.4 (2.3, 7.2)</td>... |
bb89c69d2112174cd59d8587281855b89c5007293bb8d73f7e4f4147faa75ded.png | simple | <table><tr><td>The 4 ALSI factors</td><td>Number of Questions</td><td>Mean</td><td>Mean as % of Max.</td><td>SEM</td><td>Cronbach’s α</td></tr><tr><td>Deep approach</td><td>6 Questions</td><td>19.84</td><td>66.10</td><td>0.22</td><td>0.71</td></tr><tr><td>Surface approach</td><td>4 Questions</td><td>9.57</td... |
132368b04047a1d11eb2dd8034647ea483620af3299315e890532ca786609115.png | simple | <table><tr><td>Variable</td><td>RR (CI 95%)</td><td>p value*</td></tr><tr><td>Diabetes mellitus</td><td>1.3 (0.8–2)</td><td>0.2</td></tr><tr><td>Hepatopathy</td><td>4 (2.7–5.9)</td><td>< 0.001</td></tr><tr><td>Exposure to chemotherapy</td><td>1.6 (0.9–2.7)</td><td>0.1</td></tr></table> |
f5331a02505f54a43de4622f247f055b1678806add1df79c687db0f7aa51ae64.png | simple | <table><tr><td></td><td>Energy intake (kcal/day) B (95 %-CI)</td><td>Standard. Beta (95 %-CI)</td><td><i>P</i>-value</td><td>Satiety Response (score) B (95 %-CI)</td><td>Standard. Beta (95 %-CI)</td><td><i>P</i>-value</td></tr><tr><td>Weight</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Birth ... |
9e30a721f646b323a0310b456870c6c559b584f30d52ef7a23e5293336f8733c.png | complex | <table><tr><td>Gene name</td><td colspan="2">N and D</td><td colspan="2">Medium N</td><td colspan="2">Medium D</td></tr><tr><td></td><td>Stability value*</td><td>SE</td><td>Stability value*</td><td>SE</td><td>Stability value*</td><td>SE</td></tr><tr><td>RPLPO</td><td>0.093</td><td>0.069</td><td>0.071</td><td>0.079</td>... |
1abddc2735253053b50aef49a18ab089f299b549ceaae1c7cb0248b218ada579.png | simple | <table><tr><td>Variable</td><td>Category</td><td>OR</td><td>95% CI</td></tr><tr><td>Age (ref: < 50 years)</td><td>> 50 years</td><td>0.49</td><td>0.09, 2.61</td></tr><tr><td>Gender (ref: male)</td><td>Female</td><td>0.52</td><td>0.11, 2.61</td></tr><tr><td>Albumin (ref: > 3.5)</td><td>≤3.5</td><td>16.3</... |
edcc9139314e881cea9656bc959b19432d29f8117f4d2013dec47ef7ce65dd01.png | simple | <table><tr><td></td><td>Serotonin</td><td>RANKL</td><td>P1NP</td><td>CTX</td></tr><tr><td>OVX+Saline versus SHAM+Saline</td><td>34.8% <sup>###</sup></td><td>77.6% <sup>###</sup></td><td>106% <sup>###</sup></td><td>74.4% <sup>###</sup></td></tr><tr><td>OVX+WBV versus SHAM+Saline</td><td>4.9%</td><td>4.6%</td><td>0.1%</t... |
788d34b4581b0a2dfada0f4d8cfc8a48ec2f9c3e82b4b080b0fbb75b1b6d743a.png | complex | <table><tr><td>Item</td><td colspan="4">Treatment<sup>b</sup></td><td rowspan="2">Pooled SEM</td><td colspan="3">Contrast<sup>c</sup></td></tr><tr><td></td><td>Control</td><td>LPS</td><td>LPS + Low GLP-2</td><td>LPS + High GLP-2</td><td>1</td><td>2</td><td>3</td></tr><tr><td>Duodenum, g</td><td>17.8</td><td>15.2</td><t... |
f06fb25db39405d05c4dd3e292efb064cf7ca59d3379bbef96543535f71ead8d.png | simple | <table><tr><td>SCD incidence rates per 100.000 person years</td><td>All</td><td>Men</td><td>Women</td><td>Incidence rate ratio</td><td><i>p</i>-value</td></tr><tr><td>1–35 years</td><td>2.7 (2.5–2.9)</td><td>3.6 (3.2–3.9)</td><td>1.8 (1,5–2,0)</td><td>2.0 (1.7–2.4)</td><td><0.01</td></t... |
6b256f1a4d915ae71405933c6977941efe21ea3ebf9d9433464b38f2fcc5354e.png | simple | <table><tr><td>Parameter</td><td>Healthy donors</td><td>RCC patients</td><td>Patients < pT3</td><td>Patients ≥ pT3</td></tr><tr><td>Number of leukocytes</td><td>6,260 ± 310</td><td>7,005 ± 350</td><td>6,500 ± 402</td><td>8,340 ± 563</td></tr><tr><td>Granulocytes</td><td>4,227 ± 310</td... |
c4ebc42651d173584b975c000685161d0e12b12c65e5db9796d25faa3dd4d4db.png | simple | <table><tr><td>Rank</td><td>Active substance, drug formulation</td><td>No of prescriptions</td><td>Potentially harmful or known to be harmful excipients</td></tr><tr><td>1</td><td>Gentamicin, inj solution</td><td>200</td><td>Parabens, sodium metabisulphite</td></tr><tr><td>2</td><td>Simeticone, oral suspension</td><td>... |
9556b403e6f798906059ef8d1c926afa1d31a212486272176732e0cfd9121638.png | complex | <table><tr><td></td><td colspan="2">Control</td><td colspan="2">Intervention</td><td></td></tr><tr><td></td><td>Preintervention</td><td>Postintervention</td><td>Preintervention</td><td>Postintervention</td><td>p Value</td></tr><tr><td>NOTECHS</td><td>72.09 (3.36)</td><td>70.09 (5.70)</td><td>71.62 (5.69)</td><td>75.44 ... |
67138aa4ae97959a3c628b1cfd9c4a3d30dc8acc9f91d1533099a84b82f631ba.png | complex | <table><tr><td rowspan="2">Treatment</td><td rowspan="2">Dose (mg/kg b.w.)</td><td colspan="5">Thickness of rat paw (cm)</td></tr><tr><td><i>T</i><sub>1 h</sub></td><td><i>T</i><sub>2 h</sub></td><td><i>T</i><sub>3 h</sub></td><td><i>T</i><sub>4 h</sub></td><td><i>T</i><sub>5 h</sub></td></tr><tr><td>Control</td><td> <... |
59e464547abae9d11cac4d0d131110b625730ebe65e28f6e17ab1a217636619a.png | simple | <table><tr><td>Risk factors</td><td>Incisional SSI (+)</td><td>Incisional SSI (−)</td><td>β</td><td>SE</td><td>Hazard ratio (95 % CI)</td><td><i>p</i> value</td></tr><tr><td>BMI (≥25/<25 kg/m<sup>2</sup>)</td><td>8/10</td><td>8/49</td><td>0.31</td><td>1.60</td><td>2.28 (0.57–9.04)</td><td>0.24... |
69d301de30762a8419db361e9e5092876d8c084114f6efe20e762c1e3d9bf2e9.png | complex | <table><tr><td></td><td>HV</td><td>NU</td><td>P values</td></tr><tr><td>n</td><td>35</td><td>33</td><td></td></tr><tr><td>Age [median (range)]</td><td>32 (23–78)</td><td>44 (18–78)</td><td>0.004</td></tr><tr><td>Sexe (% of female)</td><td>62 %</td><td>31 %</td><td>0.003</td></tr><tr><td>BMI [median (range)]... |
35f9406ae5935c4b6cc5904c404cdc1de9addf8516c9cf2b6bfb73a179e8a596.png | complex | <table><tr><td></td><td colspan="2">Transitions</td><td colspan="4">Transversions</td></tr><tr><td></td><td>A/G</td><td>C/T</td><td>A/C</td><td>A/T</td><td>G/C</td><td>G/T</td></tr><tr><td>Numbers of allelic sites</td><td>1,466</td><td>1,430</td><td>463</td><td>463</td><td>423</td><td>473</td></tr><tr><td>Percentage of... |
aa850fe472bfbf60bcf4e57d473162ba2a9c67b49ee5f75ff46eb8dfe40f0ce6.png | complex | <table><tr><td> </td><td colspan="3">IFN-beta clinical response</td><td>EDSS*</td><td>Relapses**</td></tr><tr><td> </td><td>N</td><td>Resp.</td><td>%</td><td> </td><td> </td></tr><tr><td>MHC2TA mRNA level decreased + HHV-6 in serum</td><td>21</td><td>5</td><td>23.8</td><td>1.5</td><td>1.2</td></tr><tr><td>MHC2TA mRNA l... |
c4850cfccba48e02bb3fba4d49220f5fa18c45eb3491f609bc8fd68f0a9ec218.png | simple | <table><tr><td>SN</td><td>Age</td><td>Vaccine</td></tr><tr><td>1</td><td>Birth (0–11 Months)</td><td>BCG</td></tr><tr><td>2</td><td>Birth (as soon as possible within 14 days of life</td><td>OPV0</td></tr><tr><td>3</td><td>6 Weeks</td><td>Pentavalent 1, OPV1</td></tr><tr><td>4</td><td>10 Weeks</td><td>Pentavalent ... |
c681be127fe81a272982bf169938d65bb25c7102a73f5f99fbee9d3a885c90de.png | complex | <table><tr><td></td><td colspan="5">Northern California Family Cohort</td></tr><tr><td></td><td>Source population</td><td>Contacted</td><td>Tier I</td><td>Tier II</td><td>Tier III</td></tr><tr><td>Number of households</td><td>11,850</td><td>1,955</td><td>499</td><td>186</td><td>30</td></tr><tr><td>Age</td><td></td><td>... |
0d35174e00a1d01a94cbea462c12edc9e0a0b817b05a89bce42110700e286caa.png | simple | <table><tr><td></td><td>2012</td><td>2013</td><td>2014</td></tr><tr><td>MTI Requests</td><td>44,970</td><td>42,919</td><td>87,549</td></tr><tr><td># Items processed</td><td>3,148,431</td><td>7,963,477</td><td>11,294,998</td></tr><tr><td>MeSH on demand requests</td><td>–</td><td>–</td><td>225,750</td></tr><t... |
21870cbac63914dcf1b2b9ea84eb6dcf978b2abd2132a1423e43e17bdd611397.png | simple | <table><tr><td>Gene</td><td>Primer sequence</td><td></td><td>Base pairs</td><td>Source</td></tr><tr><td>18S</td><td>Forward sequence</td><td>TGG TCG CTC GCT CCT CTC C</td><td>360</td><td>NR_003286</td></tr><tr><td></td><td>Reverse sequence</td><td>CGC CTG CTG CCT TCC TTG G</td><td></td><td></td></tr><tr><td>αSMA</... |
5cf9bc00a290054df126736c8a78894f68c17ff3dc9d362722128e861dfa5b38.png | simple | <table><tr><td>Exercise</td><td>Description</td></tr><tr><td>Exercise 1Relaxing</td><td>Diaphragmatic breathing and postural elements such as alignment of the midline.The patient is supine on a mat with flexed knees and arms along the chest.</td></tr><tr><td>Exercise 2Raising arm, opening and closing punches</td><td>Ly... |
5c0c45e5ea914bf613388cc8d97959fd5ca7dbf5f824a9613ea9efbece97a336.png | simple | <table><tr><td>Plantation collaboration</td><td>I</td><td>II</td><td>III</td><td>IV</td><td>V</td><td>VI</td><td>VII</td></tr><tr><td>IRS/ITN re/treatment</td><td>PL in negotiation to cover; currently covered by MCP</td><td>PL in negotiation to cover; currently covered by MCP</td><td>PL in negotiation to cover; current... |
a7e686a6efeef646b653deec2936d3b7e2bb62c3bbad635762bc375855d227e2.png | complex | <table><tr><td rowspan="3">Variables</td><td colspan="4">IHM</td></tr><tr><td colspan="2">Model 1</td><td colspan="2">Model 2</td></tr><tr><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td></tr><tr><td>Age</td><td>1.07</td><td>0.995–1.14</td><td>1.07</td><td>0.995–1.16</td></tr><tr><td>Sex</td><td>2.27</t... |
8d739c0f12e21d59bc29fad54722bab1b95d60816787caa89cd913dd02ff95e6.png | simple | <table><tr><td>Characteristics</td><td>Median (Range)</td></tr><tr><td>Age, years</td><td>70 (55-85)</td></tr><tr><td>PSA, ng/ml</td><td>24.2 (2.6-269.6)</td></tr><tr><td>Hemoglobin, g/l</td><td>124 (69-156)</td></tr><tr><td>ALP, U/l</td><td>111 (47-2779)</td></tr><tr><td>LDH, U/l</td><td>208 (114-2467)</td></tr><tr><t... |
acee4e98ab8db7d1103a06e55c8a91d42189d9305546641e9bd70204c2997647.png | complex | <table><tr><td>Primer set</td><td>Primer 1</td><td>Primer 2</td><td>FAMTM Labelled Probe</td><td>VicTM Labelled Probe</td><td>Fluorescent Quencher</td><td>Anneal (1 minute)</td></tr><tr><td><i>TGFB1 </i>-800G>A</td><td>gctatcgcctgcacacagc</td><td>aggacagaagcggtcccat</td><td>tgcctccaacgtcaccaccatc</td><td>tctgcctccaa... |
fa28cc6aae2aced3e7c5962f9954a3a45ba9cdf914f08a0f2ee7f81530bf1d02.png | simple | <table><tr><td>Inclusion criteria</td><td>Exclusion criteria</td></tr><tr><td>At least 16 years old</td><td>Present fracture or other joint pathology/bone matrix pathology</td></tr><tr><td>Visited the ER within one week after a lateral ankle sprain</td><td>A diagnosed OCD after primary inclusion</td></tr><tr><td>Agreed... |
e30e44d8d2377c1929b573edc3dd4b0f09c62e7a622067b831c754a5ee6afeba.png | complex | <table><tr><td></td><td colspan="2">PAX8 staining N (%)</td><td rowspan="2"><i>P</i>-value<sup>†</sup></td></tr><tr><td>Clinical Feature</td><td>Low/Absent</td><td>Medium/High</td></tr><tr><td>Stage</td><td></td><td></td><td></td></tr><tr><td>1</td><td>17 (30)</td><td>39 (70)</td><td>0.013*</td></tr><tr><td>2</td... |
8115e1519066d2a8c1d74ce2b7913a7703560ccfa16ca15e3084ec18d7e9d7dd.png | simple | <table><tr><td>Types of home visits</td><td>Influencing conditions and causes</td><td>Strategies to achieve “productive performance”</td><td>Consequences of “productive performance”</td></tr><tr><td>• Visits on demand• Periodic visits• Nursing home round• Visits based on ... |
ff592f2b5d3a01c8a82cfc605598c7ed9abd75570e7a6a78e8e4fcc2b4d96896.png | complex | <table><tr><td>Criteria as provided in Figure 1</td><td>Median, days (range) No. (%)</td><td>≥0 days No. (%)</td><td>>0 days No. (%)</td><td>≤0 days No. (%)</td><td>= 0 days No. (%)</td><td><0 days No. (%)</td><td>Ref.</td></tr><tr><td colspan="8"><i>Lead times</i></td></tr><tr><td colspan="8"><i>4A A... |
f9b83d66e1d34bda0555aa6aa2f2f833e011d0a832b3ae8a076cd0ea166c6a9b.png | simple | <table><tr><td>Treatments</td><td><i>invH</i></td><td><i>hilA</i></td><td><i>hilD</i></td><td><i>sipA</i></td><td><i>sipB</i></td><td><i>sopB</i></td><td><i>spvB</i></td></tr><tr><td>SE Ctrl</td><td>1 <sup>a</sup></td><td>1 <sup>a</sup></td><td>1 <sup>a</sup></td><td>1 <sup>a</sup></td><td>1 <sup>a</sup></td><td>1 <sup... |
42bb023c0f7fc6e44a38e21eabec35538491a4cc3cd871ea63b18551baf02d0b.png | complex | <table><tr><td></td><td>Instrument</td><td>Baseline (T0)</td><td>2 months (T1)</td><td>4 months (T2)</td><td>8 months (T3)</td><td>12 months (T4)</td></tr><tr><td colspan="7">Primary outcomes</td></tr><tr><td>Physical functioning</td><td>PCS of RAND-36</td><td>x</td><td>x</td><td>x</td><td></td><td>x</td></tr><tr><td>D... |
9d99184cc09e58b5d4f6c1bffd6b2690308efa507749725946c7707e9775e1df.png | complex | <table><tr><td></td><td colspan="2">Sex</td><td><i>F</i></td><td><i>p</i></td></tr><tr><td></td><td>Male</td><td>Female</td><td></td><td></td></tr><tr><td>Left</td></tr><tr><td>Anterior</td><td>1202.93 (4.21)</td><td>1180.06 (3.77)</td><td>14.92</td><td>0.0001</td></tr><tr><td>Middle</td><td>2458.53 (10.52)</td><td>245... |
51e42e2da7c5e900bea78a05706a541a6aa7897b171a8abb1a83c7d1dd71807e.png | complex | <table><tr><td></td><td>Q1:50.8 g/day (46.3, 53.6)<sup>a</sup></td><td>Q2:59.6 g/day (57.8, 61.5)<sup>a</sup></td><td>Q3:68.0 g/day (65.7, 70.4)<sup>a</sup></td><td>Q4:81.6 g/day (76.3, 89.9)<sup>a</sup></td></tr><tr><td colspan="5">Demographic and lifestyle factors</td></tr><tr><td> N (cases)</td><td>2173 (146)</td><t... |
5cb97a3f68e1a0cc22f2c40fc6d4905ee2ecc31f25a83fee3efb65a43c759818.png | complex | <table><tr><td>Characteristic</td><td>N = 981 (%)</td></tr><tr><td colspan="2">Demographics and Health Habits from Patient Survey</td></tr><tr><td>Age</td><td></td></tr><tr><td> 64–74 years</td><td>61</td></tr><tr><td> 75 + years</td><td>39</td></tr><tr><td>Race</td><td></td></tr><tr><td> Caucasian</td><td>92</td... |
fc9846bc858f4a482c3929d8a4d441038d517a69afa78ced87fa21214fa9ebd9.png | simple | <table><tr><td>References</td><td>Number of cases</td><td>Sex</td><td>Age (years)</td><td>Sites of lesion</td><td>Procedure</td><td>Recurrence</td></tr><tr><td>Verma and Paul [15]</td><td>1</td><td>F</td><td>39</td><td>Metacarpal</td><td>En bloc resection, autograft</td><td>No</td></tr><tr><td>Gebert <i>et al</i>. [16]... |
20b5b86746cde5b809a4da70bd9ddf99e93727f42f37185460efab52c6a52311.png | simple | <table><tr><td>Setup</td><td>AIC score</td><td>BIC score</td><td>HQC score</td><td>Prob. score</td></tr><tr><td>1000 individuals</td><td></td><td></td><td></td><td></td></tr><tr><td>1 mutation</td><td>0.0787 ± 0.118</td><td>0.0705 ± 0.111</td><td>0.068 ± 0.111</td><td>0.068 ± 0.103</td></tr><tr><td>... |
fe44a283fd48a66543f5b2c6562c2689fe1173e320cbe3fd7c71af0bd8d9f210.png | simple | <table><tr><td></td><td>Controls(<i>n</i> = 10)<i>n</i> (%)</td><td>Diabetes (<i>n</i> = 20) <i>n</i> (%)</td><td>New diabetes (<i>n</i> = 8) <i>n</i> (%)</td><td><i>p</i></td></tr><tr><td>MIBP</td><td>9 (90)</td><td>15 (75)</td><td>7 (88)</td><td>0.640</td></tr><tr><td>MBP</td><td>2 (20)</td><td>3 (15)</td><td>3 (38)<... |
4f4a77cf0f56b3f654be401756ca23982e74a67856b49a8319de345cbd3e7092.png | complex | <table><tr><td rowspan="2">DNA Concentration</td><td rowspan="2">n</td><td rowspan="2">N</td><td rowspan="2">Cleavage(% ± SD)</td><td>Blastocyst development</td><td>EGFP<sup>+</sup> Blastocysts</td><td>Net yield EGFP<sup>+</sup></td></tr><tr><td>(% ± SD)<sup>a</sup></td><td>(% ± SD)<sup>b</sup></td><td>B... |
8202fce481deb0cda09aba5fe5ff3e64e59e9ee49cd939cfc7c41bdf6c9628e9.png | simple | <table><tr><td>Characteristics</td><td><i>n</i></td><td>HRM me (%)</td><td>MSP me (%)</td><td>PSQ me (%)</td><td>IDH1 mut (%)</td></tr><tr><td>All patients</td><td>83</td><td>51.8</td><td>37.3</td><td>54.2</td><td>21.7</td></tr><tr><td>Woman</td><td>28</td><td>50.0</td><td>39.3</td><td>53.6</td><td>21.4</td></tr><tr><t... |
1c43ddbd66559bf3a1fb625f95bff469daa89031e06bf1b8dab205b1d13095bf.png | simple | <table><tr><td>Age Range</td><td>Number</td><td>Percentage (%)</td></tr><tr><td>1-10</td><td>9</td><td>42.9</td></tr><tr><td>11-20</td><td>5</td><td>23.8</td></tr><tr><td>21-30</td><td>7</td><td>33.3</td></tr><tr><td>Total</td><td>21</td><td>100</td></tr></table> |
aa10e72072738a81e38352bb569e44a813d8d7a074b357ce1960dba47aed2caf.png | complex | <table><tr><td>Authors (year of publication)</td><td>Population studied with CD</td><td>Prevalence of thyroid dysfunction</td></tr><tr><td rowspan="3">Collin et al. (1994) [19]</td><td>355</td><td>AITD* (19) 5.4%</td></tr><tr><td></td><td>Autoimmune hypothyroidism (11) 3.1%</td></tr><tr><td></td><td>Graves' disease (7)... |
bfe8057e72cbc43b57bc13218d4a8815983aa1b512daed5a6e14c107c120fa1d.png | complex | <table><tr><td></td><td colspan="3">Source of help beforehand</td><td colspan="3">Source of help afterwards</td></tr><tr><td></td><td>N = 558*</td><td>N = 137*</td><td>N = 421*</td><td>N = 526*</td><td>N = 133*</td><td>N = 393*</td></tr><tr><td></td><td>N (%)</td><td>Male (%)</td><td>Female (%)</td><td>N (%)</td><td>Ma... |
828de89f52ec0d03820c906f40b670f2f817236cfe570a55a9493e94ee5dd667.png | complex | <table><tr><td></td><td colspan="3">SCQ total</td><td colspan="3">SRS raw score</td></tr><tr><td><i>Factors</i></td><td><i>B</i></td><td><i>p</i></td><td>95%</td><td><i>B</i></td><td><i>p</i></td><td>95%</td></tr><tr><td>Constant</td><td>12.44</td><td>0.204</td><td>− 7.38/32.25</td><td>− 21.43</td><td>0.615... |
44eb94deb13d481771d1622c9126ae2daedd2331e03436e300d82e6bef562353.png | complex | <table><tr><td></td><td colspan="3">GP profession</td><td></td><td></td><td></td><td></td></tr><tr><td># new patients consulted</td><td>US</td><td>UK</td><td>Germany</td><td>France</td><td>Spain</td><td>Italy</td><td>GP total</td></tr><tr><td>0</td><td>20</td><td>5</td><td>2</td><td>-</td><td>1</td><td>1</td><td>29</td... |
0f894d668a159b8c60b39796bab099e28064094a5dd9807e4be621e99fcdf6fc.png | complex | <table><tr><td>Site</td><td>Characteristic</td><td>Category</td><td>Unadjusted OR (95% CI)</td></tr><tr><td rowspan="9">Nouna</td><td>Malaria treatment in past 14 days</td><td>Yes vs no</td><td>0.323 (0.215, 0.484)</td></tr><tr><td>Other medication in the past 14 days</td><td>Yes vs no</td><td>0.563 (0.403, 0.788)</td>... |
ef681d4e74b2b72f83631f7ff965e66379550e85162f867b1e6feef9c1d5eb75.png | simple | <table><tr><td>Allele</td><td>Slope</td><td>Efficiency (%)</td><td><i>R</i><sup>2</sup></td><td><i>y</i>-intercepts</td></tr><tr><td>Wild-type-sensitive</td><td>3.39</td><td>97.2</td><td>0.998</td><td>37.705</td></tr><tr><td>Mutant-resistant</td><td>2.59</td><td>142.7</td><td>0.991</td><td>36.531</td></tr></table> |
8c0dd92b8a307ae3f5c87438b23d5dca8e8b9de6421a9a12db30e8828804b562.png | simple | <table><tr><td></td><td>Women</td><td>Men</td><td>All</td></tr><tr><td>N</td><td>32</td><td>27</td><td>59</td></tr><tr><td>Age (years)</td><td>39.3 ± 10.5</td><td>39.3 ± 11.0</td><td>39.3 ± 10.6</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>23.2 ± 3.1</td><td>25.8 ± 3.6**</td><td>... |
9d453dbbb0ecff3e71c45bce96b7e63b42546b647dd2faef0f00f467da40820d.png | simple | <table><tr><td></td><td>cTAKES [4]</td><td>NOBLE Coder [20]</td><td>MetaMap [31, 32]</td><td>NCBO annotator [14]</td></tr><tr><td>Modularity/configuration options</td><td>Modular text processing pipeline</td><td>Vocabulary (terminology);Term matching options and strategies</td><td>Text processing pipeline;Vocabulary (t... |
0995497eb43985d4654fa71f7f615eade325f331e6c530eda96ed30f6afb15bd.png | simple | <table><tr><td>Eukaryotic organisms</td><td>%</td><td>Prokaryotic organisms</td><td>%</td></tr><tr><td><i>Chloromonas pseudoplatyrhyncha</i></td><td>26.93</td><td><i>Rhodoferax</i> sp.</td><td>21.94</td></tr><tr><td><i>Stephanodiscus</i> sp.</td><td>18.17</td><td>Unsequenced organisms</td><td>17.84</td></tr><tr><td>Uns... |
fb0c6e0caf71001e43b2b06573f16cb352f0905d3fef89f8d8381aa1c0f062a1.png | simple | <table><tr><td> </td><td>Women using long-acting reversible contraception<sup>+</sup>(<i>n</i> = 866)Percentage</td><td>Women using highly effective short-term reversible contraception<sup>∧</sup> (<i>n</i> = 12,098)Percentage</td><td>UnivariableOR (95% CI)</td><td>Multivariable OR (95% CI)</td></tr><tr><td>Age<s... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.